Cerity Partners
KRYS icon

Cerity Partners’s Krystal Biotech KRYS Stock Holding History

Cerity Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$706K Buy
+1,899
New +$567K ﹤0.01% 2214
2026
Q1 		– Sell
-1,361
Closed -$336K – 3329
2025
Q4 		$336K Buy
+1,361
New +$286K ﹤0.01% 2345
2024
Q4 		– Sell
-1,542
Closed -$281K – 2524
2024
Q3 		$281K Buy
+1,542
New +$297K ﹤0.01% 2101

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cerity Partners's KRYS Position: Q2 2026 in Review

Cerity Partners opened a new position in Krystal Biotech (KRYS) in Q2 2026: 1,899 shares worth $706K. The stake represents ﹤0.01% of the portfolio and ranks #2214 among its holdings. This is a return to the name: Cerity Partners previously reported a position in KRYS as recently as Q4 2025.

Cerity Partners first reported a position in KRYS in Q3 2024 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cerity Partners held 1,899 shares of Krystal Biotech worth $706K as of Q2 2026.
  • Krystal Biotech was a new Cerity Partners position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2214 holding.
  • Cerity Partners first reported a position in Krystal Biotech in Q3 2024 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.